首页 > 最新文献

Ophthalmology. Glaucoma最新文献

英文 中文
The Evolution of Visual Field Testing 视野测试的演变:40年来青光眼的现代视野测量。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.1016/j.ogla.2025.08.001
Anfei Li MD, PhD , C. Gustavo De Moraes MD, PhD
The assessment of the human visual field, a concept explored since ancient Greece, underwent a critical transformation in the 19th century with the advent of objective measurement techniques. Early methodologies concentrated on mapping the outer limits of vision, a practice known as perimetry. However, the focus soon shifted toward campimetry (although the name perimetry remained), which involves assessing defects within the central/paracentral visual field—a crucial development for diagnosing diseases such as glaucoma. Although historical methods such as Bjerrum tangent screen and Goldmann kinetic perimetry were foundational, the last 4 decades have been defined by the rise of static automated perimetry (SAP). Coinciding with the inception of the American Glaucoma Society, the 1980s marked a pivotal transition from manual techniques to computerized, automated testing. Static automated perimetry, exemplified by the Humphrey Field Analyzer (HFA), has since become the clinical standard, offering a precise and reproducible method for quantifying visual field sensitivities, which is indispensable for the detection and management of glaucoma. This review examines the evolution of modern visual field testing over the past 40 years, focusing on the technological advancements in hardware, software algorithms, and novel testing paradigms that have reshaped our approach to glaucoma care.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
人类视野的评估是一个自古希腊以来就被探索的概念,随着客观测量技术的出现,在19世纪经历了一个关键的转变。早期的方法集中于绘制视觉的外部界限,这种做法被称为视野测量。然而,焦点很快转向了视野测量(尽管名称仍然保留),它涉及评估中央/副中央视野内的缺陷——这是诊断青光眼等疾病的关键发展。虽然Bjerrum切线筛和Goldmann动力学视野测量等历史方法是基础,但在过去的40年里,静态自动视野测量(SAP)的兴起定义了这一方法。20世纪80年代恰逢美国青光眼协会成立,标志着从手工技术到计算机化、自动化测试的关键转变。以汉弗莱视场分析仪(Humphrey Field Analyzer, HFA)为代表的静态自动视场测量从此成为临床标准,提供了一种精确、可重复的量化视野灵敏度的方法,这对于青光眼的检测和治疗是不可或缺的。本文回顾了过去40年来现代视野检测的发展,重点介绍了硬件、软件算法和新的检测范式方面的技术进步,这些技术进步重塑了我们对青光眼的治疗方法。财务披露:专有或商业披露可在本文末尾的脚注和披露中找到。
{"title":"The Evolution of Visual Field Testing","authors":"Anfei Li MD, PhD ,&nbsp;C. Gustavo De Moraes MD, PhD","doi":"10.1016/j.ogla.2025.08.001","DOIUrl":"10.1016/j.ogla.2025.08.001","url":null,"abstract":"<div><div>The assessment of the human visual field, a concept explored since ancient Greece, underwent a critical transformation in the 19th century with the advent of objective measurement techniques. Early methodologies concentrated on mapping the outer limits of vision, a practice known as perimetry. However, the focus soon shifted toward campimetry (although the name <em>perimetry</em> remained), which involves assessing defects within the central/paracentral visual field—a crucial development for diagnosing diseases such as glaucoma. Although historical methods such as Bjerrum tangent screen and Goldmann kinetic perimetry were foundational, the last 4 decades have been defined by the rise of static automated perimetry (SAP). Coinciding with the inception of the American Glaucoma Society, the 1980s marked a pivotal transition from manual techniques to computerized, automated testing. Static automated perimetry, exemplified by the Humphrey Field Analyzer (HFA), has since become the clinical standard, offering a precise and reproducible method for quantifying visual field sensitivities, which is indispensable for the detection and management of glaucoma. This review examines the evolution of modern visual field testing over the past 40 years, focusing on the technological advancements in hardware, software algorithms, and novel testing paradigms that have reshaped our approach to glaucoma care.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages S20-S26"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Glaucoma Society 40th Anniversary 美国青光眼协会成立40周年:前言。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.1016/j.ogla.2025.08.007
Carla J. Siegfried MD, Gregory L. Skuta MD
{"title":"American Glaucoma Society 40th Anniversary","authors":"Carla J. Siegfried MD,&nbsp;Gregory L. Skuta MD","doi":"10.1016/j.ogla.2025.08.007","DOIUrl":"10.1016/j.ogla.2025.08.007","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Page S1"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of CYP1B1 Variants on Phenotypic Characteristics and Therapeutic Outcomes in Primary Congenital Glaucoma CYP1B1变异对原发性先天性青光眼表型特征和治疗结果的影响
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-05-09 DOI: 10.1016/j.ogla.2025.04.012
Rita Rodrigues MD , David Alves MD , João Esteves-Leandro MD , Marta Silva MD , João Barbosa-Breda MD, PhD , João Tavares-Ferreira MD , Joana Araújo MD , Susana Fernandes PhD , Renata Oliveira MD , António Melo MD , Flávio Alves MD , Augusto Magalhães MD , José Cotta MD , Sérgio Estrela-Silva MD
<div><h3>Purpose</h3><div>To identify <span><span>CYP1B1</span></span><span> variants in primary congenital glaucoma (PCG) patients from Northern Portugal and examine genotype–phenotype correlations.</span></div></div><div><h3>Design</h3><div>Cross sectional observational study.</div></div><div><h3>Participants</h3><div>Seventy-one patients diagnosed and treated for PCG at ULS São João, Porto, Portugal, were included. These patients met the following criteria: available genetic testing data, a minimum follow-up period of 1 year, and the last appointment between January 2022 and January 2024.</div></div><div><h3>Methods</h3><div>Demographic and clinical data were collected. <em>CYP1B1</em><span> variants were screened using DNA sequencing. A next-generation sequencing (NGS) glaucoma panel was performed in patients with heterozygous or absent </span><em>CYP1B1</em> variants in the screening. Genotype–phenotype correlations were assessed by comparing clinical characteristics between patients with identified biallelic plausible disease-causing variants in <em>CYP1B1</em> variants and those with negative genetic testing results.</div></div><div><h3>Main Outcome Measures</h3><div><em>CYP1B1</em><span> variants, sex, laterality, age at diagnosis, age at first surgery, number of surgical procedures, number of intraocular pressure (IOP)-lowering medications, IOP at last follow-up, and final best-corrected visual acuity (BCVA).</span></div></div><div><h3>Results</h3><div><span>Sixty-six unrelated probands and 5 affected relatives (133 eyes) were analyzed. Two plausible disease-causing </span><em>CYP1B1</em> variants were identified in 60.6% (43/71) of patients. Nineteen distinct <em>CYP1B1</em> variants were identified, including 4 novel variants. The most frequent variants were c.535del (43.5%) and c.1200_1209dup (28.2%). Compared with negative genetic testing group (n = 22), patients with <em>CYP1B1</em> variants (n = 43) showed significantly higher rates of bilateral disease (100% vs. 68%, <em>P</em> < 0.001), earlier disease onset (median 0 vs. 5.5 months, <em>P</em> < 0.001), poorer final BCVA (median 0.5 vs. 0.25 logarithm of the minimum angle of resolution, <em>P</em> = 0.025), higher IOP at last follow-up (median 16 vs. 12 mmHg, <em>P</em> < 0.001), and greater need for surgical interventions (median 2 vs. 1, <em>P</em> = 0.014) and IOP-lowering medications (median 2 vs. 0, <em>P</em> = 0.005). Next-generation sequencing testing in <em>CYP1B1</em>-negative patients identified 3 novel heterozygous variants of uncertain significance in the TEK gene.</div></div><div><h3>Conclusions</h3><div>Primary congenital glaucoma patients from Northern Portugal with <em>CYP1B1</em> variants are more likely to present with bilateral disease, earlier onset, and a more severe clinical phenotype, suggesting a strong genotype–phenotype correlation.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in a
目的:鉴定葡萄牙北部原发性先天性青光眼(PCG)患者的CYP1B1变异,并检查基因型与表型的相关性。设计:横断面观察性研究。参与者:71例在葡萄牙波尔图的 o jo s诊断和治疗的PCG患者。这些患者符合以下标准:可获得基因检测数据,至少随访1年,最后一次预约时间为2022年1月至2024年1月。方法:收集人口学和临床资料。使用DNA测序筛选CYP1B1变异体。下一代测序(NGS)青光眼小组在筛选中杂合或缺失CYP1B1变异的患者中进行。通过比较在CYP1B1变异中确定的双等位基因似是而非的致病变异的患者与基因检测结果为阴性的患者的临床特征,评估基因型-表型相关性。主要观察指标:CYP1B1变异、性别、侧边、诊断时年龄、首次手术年龄、手术次数、降眼压药物次数、最后随访时眼压、最终最佳矫正视力(BCVA)。结果:对66例无血缘关系先证者和5例患病亲属(133眼)进行分析。60.6%(43/71)的患者发现了两种可能致病的CYP1B1变异。鉴定出19种不同的CYP1B1变异,包括4种新的变异。最常见的变异是c.535del(43.5%)和c.1200_1209dup(28.2%)。与基因检测阴性组(n=22)相比,CYP1B1变异患者(n=43)的双侧疾病发生率明显更高(100% vs 68%, p结论:来自葡萄牙北部的CYP1B1变异的PCG患者更容易出现双侧疾病,发病更早,临床表型更严重,提示基因型-表型相关性强。
{"title":"Influence of CYP1B1 Variants on Phenotypic Characteristics and Therapeutic Outcomes in Primary Congenital Glaucoma","authors":"Rita Rodrigues MD ,&nbsp;David Alves MD ,&nbsp;João Esteves-Leandro MD ,&nbsp;Marta Silva MD ,&nbsp;João Barbosa-Breda MD, PhD ,&nbsp;João Tavares-Ferreira MD ,&nbsp;Joana Araújo MD ,&nbsp;Susana Fernandes PhD ,&nbsp;Renata Oliveira MD ,&nbsp;António Melo MD ,&nbsp;Flávio Alves MD ,&nbsp;Augusto Magalhães MD ,&nbsp;José Cotta MD ,&nbsp;Sérgio Estrela-Silva MD","doi":"10.1016/j.ogla.2025.04.012","DOIUrl":"10.1016/j.ogla.2025.04.012","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To identify &lt;span&gt;&lt;span&gt;CYP1B1&lt;/span&gt;&lt;/span&gt;&lt;span&gt; variants in primary congenital glaucoma (PCG) patients from Northern Portugal and examine genotype–phenotype correlations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Cross sectional observational study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Seventy-one patients diagnosed and treated for PCG at ULS São João, Porto, Portugal, were included. These patients met the following criteria: available genetic testing data, a minimum follow-up period of 1 year, and the last appointment between January 2022 and January 2024.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Demographic and clinical data were collected. &lt;em&gt;CYP1B1&lt;/em&gt;&lt;span&gt; variants were screened using DNA sequencing. A next-generation sequencing (NGS) glaucoma panel was performed in patients with heterozygous or absent &lt;/span&gt;&lt;em&gt;CYP1B1&lt;/em&gt; variants in the screening. Genotype–phenotype correlations were assessed by comparing clinical characteristics between patients with identified biallelic plausible disease-causing variants in &lt;em&gt;CYP1B1&lt;/em&gt; variants and those with negative genetic testing results.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;&lt;em&gt;CYP1B1&lt;/em&gt;&lt;span&gt; variants, sex, laterality, age at diagnosis, age at first surgery, number of surgical procedures, number of intraocular pressure (IOP)-lowering medications, IOP at last follow-up, and final best-corrected visual acuity (BCVA).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Sixty-six unrelated probands and 5 affected relatives (133 eyes) were analyzed. Two plausible disease-causing &lt;/span&gt;&lt;em&gt;CYP1B1&lt;/em&gt; variants were identified in 60.6% (43/71) of patients. Nineteen distinct &lt;em&gt;CYP1B1&lt;/em&gt; variants were identified, including 4 novel variants. The most frequent variants were c.535del (43.5%) and c.1200_1209dup (28.2%). Compared with negative genetic testing group (n = 22), patients with &lt;em&gt;CYP1B1&lt;/em&gt; variants (n = 43) showed significantly higher rates of bilateral disease (100% vs. 68%, &lt;em&gt;P&lt;/em&gt; &lt; 0.001), earlier disease onset (median 0 vs. 5.5 months, &lt;em&gt;P&lt;/em&gt; &lt; 0.001), poorer final BCVA (median 0.5 vs. 0.25 logarithm of the minimum angle of resolution, &lt;em&gt;P&lt;/em&gt; = 0.025), higher IOP at last follow-up (median 16 vs. 12 mmHg, &lt;em&gt;P&lt;/em&gt; &lt; 0.001), and greater need for surgical interventions (median 2 vs. 1, &lt;em&gt;P&lt;/em&gt; = 0.014) and IOP-lowering medications (median 2 vs. 0, &lt;em&gt;P&lt;/em&gt; = 0.005). Next-generation sequencing testing in &lt;em&gt;CYP1B1&lt;/em&gt;-negative patients identified 3 novel heterozygous variants of uncertain significance in the TEK gene.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Primary congenital glaucoma patients from Northern Portugal with &lt;em&gt;CYP1B1&lt;/em&gt; variants are more likely to present with bilateral disease, earlier onset, and a more severe clinical phenotype, suggesting a strong genotype–phenotype correlation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Financial Disclosure(s)&lt;/h3&gt;&lt;div&gt;The authors have no proprietary or commercial interest in a","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages 457-465"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meaningful Patient Partnerships 有意义的患者伙伴关系:青光眼手术患者观点和共同决策的定性研究。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-04-18 DOI: 10.1016/j.ogla.2025.04.006
Zayn Al-Timimi BMed, MD , Samrat Sarkar BOptom, MAppSc , Sapna Nand BAppSc(Orth) , Simon E. Skalicky MBBS, PhD , Sartaj Sandhu MBBS , Hamish Dunn MBBS, PhD , Lisa Keay MPH, PhD

Purpose

Patient-centered care is key to successful clinical outcomes and meaningful clinician–patient relationships. Accordingly, a comprehensive understanding of patient perspectives is essential to aligning the clinician's focus and patient's goals. However, our understanding of patients' perceptions of glaucoma surgery and involvement in surgical decision-making has not kept pace with the rapid treatment advances in the field and move toward earlier surgery with the advent of minimally invasive glaucoma surgery devices. The purpose of this study was to understand the perspectives and priorities of people with glaucoma when considering glaucoma surgery through qualitative analysis of semistructured interviews.

Design

A qualitative study.

Participants

Individuals diagnosed with glaucoma, above 18 years of age, and able to communicate effectively in English. Interviews were conducted with 40 participants: 23 participants who had undergone glaucoma surgery and 17 who had not.

Methods

Interviews were conducted over telephone, using an interview guide developed in consultation with people with glaucoma and surgeons. The cohort was purposely sampled to ensure representation across age, sex, socioeconomic status, remoteness, glaucoma severity, clinic settings, and treatment histories. Transcripts were iteratively analyzed to identify key themes pertaining to perceptions of glaucoma surgery and involvement in decision-making.

Main Outcome Measures

Surgical perception and involvement themes, including barriers and bridges to confidence in glaucoma surgery.

Results

Six key themes were identified: (1) patients feeling rushed; (2) onus on the patient to seek information; (3) undercurrents of anxiety; (4) perceptions of surgery shaped by understanding and expectations of the disease and its treatment paradigm; (5) trust in surgeon imbuing confidence in surgery; and (6) empowerment through understanding of alternatives. Key barriers to patient involvement included patient anxiety, time pressures (real or perceived), and perceived urgency of intervention.

Conclusions

Shared decision-making in glaucoma surgery remains aspirational. This study provides valuable insights into patient perceptions of glaucoma surgery, which can help inform patient-centered care. Readily applicable “practice points” are proposed to optimize patient involvement and empowerment.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
目的:以患者为中心的护理是成功的临床结果和有意义的医患关系的关键。因此,全面了解患者的观点对于调整临床医生的重点和患者的目标至关重要。然而,随着微创青光眼手术设备的出现,我们对患者对青光眼手术的看法和参与手术决策的理解并没有跟上该领域治疗的快速发展,也没有向早期手术发展。本研究的目的是通过半结构化访谈的定性分析,了解青光眼患者在考虑青光眼手术时的观点和优先事项。设计:定性研究。参与者:被诊断为青光眼的个体,18岁以上,能够用英语进行有效沟通。对40名参与者进行了访谈:23名参与者接受了青光眼手术,17名没有。方法:采用与青光眼患者和外科医生协商制定的访谈指南,通过电话进行访谈。该队列的抽样是有目的的,以确保年龄、性别、社会经济地位、偏远地区、青光眼严重程度、诊所设置和治疗史的代表性。反复分析转录本,以确定与青光眼手术和参与决策有关的关键主题。主要结果测量:手术感知和受累主题,包括青光眼手术信心的障碍和桥梁。结果:确定了6个关键主题:(1)患者感觉匆忙;(二)患者查询信息的责任;(3)焦虑潜流;(4)对手术的认知受对疾病及其治疗模式的理解和期望的影响;(五)对外科医生的信任,对手术充满信心;(6)通过理解替代方案来授权。患者参与的主要障碍包括患者焦虑,时间压力(真实的或感知的),以及感知到的干预紧迫性。结论:青光眼手术的共同决策仍然是理想的。本研究为患者对青光眼手术的看法提供了有价值的见解,有助于为以患者为中心的护理提供信息。提出了易于应用的“实践点”,以优化患者参与和授权。财务披露:专有或商业披露可在本文末尾的脚注和披露中找到。
{"title":"Meaningful Patient Partnerships","authors":"Zayn Al-Timimi BMed, MD ,&nbsp;Samrat Sarkar BOptom, MAppSc ,&nbsp;Sapna Nand BAppSc(Orth) ,&nbsp;Simon E. Skalicky MBBS, PhD ,&nbsp;Sartaj Sandhu MBBS ,&nbsp;Hamish Dunn MBBS, PhD ,&nbsp;Lisa Keay MPH, PhD","doi":"10.1016/j.ogla.2025.04.006","DOIUrl":"10.1016/j.ogla.2025.04.006","url":null,"abstract":"<div><h3>Purpose</h3><div>Patient-centered care is key to successful clinical outcomes and meaningful clinician–patient relationships. Accordingly, a comprehensive understanding of patient perspectives is essential to aligning the clinician's focus and patient's goals. However, our understanding of patients' perceptions of glaucoma surgery<span> and involvement in surgical decision-making has not kept pace with the rapid treatment advances in the field and move toward earlier surgery with the advent of minimally invasive glaucoma surgery devices. The purpose of this study was to understand the perspectives and priorities of people with glaucoma when considering glaucoma surgery through qualitative analysis of semistructured interviews.</span></div></div><div><h3>Design</h3><div>A qualitative study.</div></div><div><h3>Participants</h3><div>Individuals diagnosed with glaucoma, above 18 years of age, and able to communicate effectively in English. Interviews were conducted with 40 participants: 23 participants who had undergone glaucoma surgery and 17 who had not.</div></div><div><h3>Methods</h3><div>Interviews were conducted over telephone, using an interview guide developed in consultation with people with glaucoma and surgeons. The cohort was purposely sampled to ensure representation across age, sex, socioeconomic status, remoteness, glaucoma severity, clinic settings, and treatment histories. Transcripts were iteratively analyzed to identify key themes pertaining to perceptions of glaucoma surgery and involvement in decision-making.</div></div><div><h3>Main Outcome Measures</h3><div>Surgical perception and involvement themes, including barriers and bridges to confidence in glaucoma surgery.</div></div><div><h3>Results</h3><div>Six key themes were identified: (1) patients feeling rushed; (2) onus on the patient to seek information; (3) undercurrents of anxiety; (4) perceptions of surgery shaped by understanding and expectations of the disease and its treatment paradigm; (5) trust in surgeon imbuing confidence in surgery; and (6) empowerment through understanding of alternatives. Key barriers to patient involvement included patient anxiety, time pressures (real or perceived), and perceived urgency of intervention.</div></div><div><h3>Conclusions</h3><div>Shared decision-making in glaucoma surgery remains aspirational. This study provides valuable insights into patient perceptions of glaucoma surgery, which can help inform patient-centered care. Readily applicable “practice points” are proposed to optimize patient involvement and empowerment.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages 440-449"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood Glaucoma 儿童青光眼。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-08-06 DOI: 10.1016/j.ogla.2025.06.011
James D. Brandt MD , Lauren S. Blieden MD , Alana L. Grajewski MD
The glaucomas arising in children comprise a diverse group of developmental and secondary disorders. Until the mid-20th century, childhood glaucoma was a uniformly blinding disease. The development of surgical approaches like goniotomy ab interno (1940s) and trabeculotomy ab externo (1960s) provided the first effective treatments for this group of uncommon disorders. Since then, additional progress in the management of adult glaucoma has quickly found its way to childhood glaucoma—including the use of antimetabolites, modern glaucoma drainage devices, and techniques of circumferential ab interno and ab externo trabeculotomy using sutures or an illuminated microcatheter. Each of these techniques requires modifications to be safely used in infants and young children. The nomenclature and classification of the pediatric glaucomas were standardized in 2013 with the Childhood Glaucoma Research Network classification system which was a foundational step in developing registries and coordinated research in the field. Modern tools of molecular genetics have begun to elucidate the underlying molecular pathophysiology and inheritance of some forms of childhood glaucoma. Single-gene, Mendelian-inherited forms of childhood glaucoma may be ideal targets for clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technologies to correct the disorder locally in the anterior chamber angle. All these advances greatly improved visual outcomes in childhood glaucoma. However, with the greatly improved visual prognosis in childhood glaucoma come unique considerations in how we care for these patients over a very long lifespan.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
儿童青光眼包括多种发育性和继发性疾病。直到20世纪中期,儿童青光眼一直是一种致盲疾病。手术入路的发展,如子宫内切开术(20世纪40年代)和外小梁切开术(20世纪60年代),为这组罕见疾病提供了第一次有效的治疗方法。从那时起,成人青光眼的治疗取得了新的进展,包括使用抗代谢物,现代青光眼引流装置,以及使用缝合线或照明微导管进行小梁内外周切开术。这些技术中的每一种都需要经过修改才能安全地用于婴幼儿。儿童青光眼的命名和分类于2013年通过儿童青光眼研究网络分类系统进行了标准化,这是在该领域开展注册和协调研究的基础步骤。现代分子遗传学工具已经开始阐明某些形式的儿童青光眼的潜在分子病理生理和遗传。单基因孟德尔遗传形式的儿童青光眼可能是聚集规律间隔短回文重复序列(CRISPR)基因编辑技术在前房角局部纠正疾病的理想目标。所有这些进展都极大地改善了儿童青光眼的视力结果。然而,随着儿童青光眼视力预后的大大改善,我们在如何长期护理这些患者时需要考虑到一些独特的问题。财务披露:专有或商业披露可在本文末尾的脚注和披露中找到。
{"title":"Childhood Glaucoma","authors":"James D. Brandt MD ,&nbsp;Lauren S. Blieden MD ,&nbsp;Alana L. Grajewski MD","doi":"10.1016/j.ogla.2025.06.011","DOIUrl":"10.1016/j.ogla.2025.06.011","url":null,"abstract":"<div><div>The glaucomas arising in children comprise a diverse group of developmental and secondary disorders. Until the mid-20th century, childhood glaucoma was a uniformly blinding disease. The development of surgical approaches like goniotomy ab interno (1940s) and trabeculotomy ab externo (1960s) provided the first effective treatments for this group of uncommon disorders. Since then, additional progress in the management of adult glaucoma has quickly found its way to childhood glaucoma—including the use of antimetabolites, modern glaucoma drainage devices, and techniques of circumferential ab interno and ab externo trabeculotomy using sutures or an illuminated microcatheter. Each of these techniques requires modifications to be safely used in infants and young children. The nomenclature and classification of the pediatric glaucomas were standardized in 2013 with the Childhood Glaucoma Research Network classification system which was a foundational step in developing registries and coordinated research in the field. Modern tools of molecular genetics have begun to elucidate the underlying molecular pathophysiology and inheritance of some forms of childhood glaucoma. Single-gene, Mendelian-inherited forms of childhood glaucoma may be ideal targets for clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technologies to correct the disorder locally in the anterior chamber angle. All these advances greatly improved visual outcomes in childhood glaucoma. However, with the greatly improved visual prognosis in childhood glaucoma come unique considerations in how we care for these patients over a very long lifespan.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages S58-S63"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Eye Drop–Treated Diseases and Conditions That Can Impair Eye Drop Self-Administration 眼药水治疗的疾病和状况会损害眼药水的自我管理。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-04-08 DOI: 10.1016/j.ogla.2025.04.001
Tianyi Wang BA , Hong Su An PhD , Jaqueline Stoutin MD , Alexander D. Valentine MD , Leah K. Depperschmidt RN , Matthew Callewaert OD , Michael Goldstein MD , Joshua D. Stein MD, MS

Objective

Eye drops are often first-line treatment for glaucoma and dry eye disease (DED). Unfortunately, proper eye drop self-administration is difficult, and this is likely magnified in persons with comorbid rheumatological, neurological, or cognitive disorders. This study investigates the association between ocular conditions often treated with eye drops (glaucoma and DED) and medical conditions that may impair proper eye drop self-administration.

Design

A retrospective database study.

Participants

From 6 health systems, 1 446 229 patients participated in the Sight Outcomes Research Collaborative between January 2012 and December 2021.

Methods

We determined the proportion of patients with glaucoma or DED with medical conditions that may limit proper eye drop self-administration and created multivariable logistic regression models assessing associations between glaucoma or DED and comorbid conditions.

Main Outcome Measures

Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) of glaucoma or DED.

Results

Among 247 899 patients with glaucoma (mean [standard deviation] age: 60.1 [15.1] years, 56.2% female, 19.5% Black), 106 927 (43%) had ≥ 1 comorbid condition that could affect eye drop self-administration. Among 321 941 patients with DED (mean [standard deviation] age: 55.9 [16.1] years, 66.4% female, 12.6% Black), 156 811 (49%) had ≥ 1 such condition. Patients with ≥ 1 impairment affecting eye drop self-administration had 17% greater odds of glaucoma (aOR: 1.17, CI: 1.16–1.18) and 66% greater odds of DED (aOR: 1.66, CI: 1.65–1.68), compared with other patients. Persons with 2, 3, and ≥ 4 conditions that may affect eye drop administration had 27%, 39%, and 53% higher odds of glaucoma, respectively, compared with persons without such conditions (P < 0.0001). Persons with 2, 3, and ≥ 4 health conditions that may impair eye drop administration had 76%, 121%, and 156% higher odds of DED, respectively (P < 0.0001).

Conclusions

Nearly half of all patients with glaucoma or DED have ≥ 1 medical condition that may impair eye drop self-administration. Clinicians should assess patients' physical and mental capacity to self-administer topical ocular therapy. Some patients may benefit from alternative therapies that reduce or eliminate the need for eye drops.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
目的:青光眼和干眼病(DED)的一线治疗通常是滴眼液。不幸的是,适当的滴眼液自我给药是困难的,这在患有风湿病、神经或认知障碍的患者中可能会更加严重。本研究调查了经常用眼药水治疗的眼部疾病(青光眼和DED)与可能损害适当滴眼液自我给药的医疗状况之间的关系。设计:回顾性数据库研究参与者:2012年1月至2021年12月期间参加视力结局研究合作(SOURCE)的6个卫生系统的1,446,229名患者。方法:我们确定了青光眼或DED患者中存在可能限制适当滴眼液自我使用的医疗条件的比例,并创建了多变量logistic回归模型,评估青光眼或DED与合并症之间的关系。结果:在247899例青光眼患者(平均(SD)年龄:60.1(15.1)岁,56.2%为女性,19.5%为黑人)中,106927例(43%)患者存在≥1种影响滴眼液自我给药的合并症。在321,941例DED患者中(平均(SD)年龄:55.9(16.1)岁,女性66.4%,黑人12.6%),156,811例(49%)有≥1种可能妨碍滴眼液自我给药的情况。与无上述情况的患者相比,有≥1种损害影响滴眼液自我给药的患者发生青光眼的几率(aOR)高17% (1.17,CI(1.16-1.18)),发生DED的几率高66% (aOR 1.66, CI 1.65-1.68))。患有2、3、4+种可能影响滴眼液给药的疾病的患者患青光眼的几率分别比没有这些疾病的患者高27%、39%和53%(结论:近一半的青光眼或DED患者患有≥1种可能影响滴眼液自我给药的疾病)。这突出了临床医生评估患者的重要性,以确保他们在身体和精神上能够自我使用眼药水。其中一些患者可能会受益于替代疗法,减少或消除对滴眼液的需求。
{"title":"Association of Eye Drop–Treated Diseases and Conditions That Can Impair Eye Drop Self-Administration","authors":"Tianyi Wang BA ,&nbsp;Hong Su An PhD ,&nbsp;Jaqueline Stoutin MD ,&nbsp;Alexander D. Valentine MD ,&nbsp;Leah K. Depperschmidt RN ,&nbsp;Matthew Callewaert OD ,&nbsp;Michael Goldstein MD ,&nbsp;Joshua D. Stein MD, MS","doi":"10.1016/j.ogla.2025.04.001","DOIUrl":"10.1016/j.ogla.2025.04.001","url":null,"abstract":"<div><h3>Objective</h3><div>Eye drops are often first-line treatment for glaucoma and dry eye disease (DED). Unfortunately, proper eye drop self-administration is difficult, and this is likely magnified in persons with comorbid rheumatological, neurological, or cognitive disorders. This study investigates the association between ocular conditions often treated with eye drops (glaucoma and DED) and medical conditions that may impair proper eye drop self-administration.</div></div><div><h3>Design</h3><div>A retrospective database study.</div></div><div><h3>Participants</h3><div>From 6 health systems, 1 446 229 patients participated in the Sight Outcomes Research Collaborative between January 2012 and December 2021.</div></div><div><h3>Methods</h3><div>We determined the proportion of patients with glaucoma or DED with medical conditions that may limit proper eye drop self-administration and created multivariable logistic regression models assessing associations between glaucoma or DED and comorbid conditions.</div></div><div><h3>Main Outcome Measures</h3><div>Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) of glaucoma or DED.</div></div><div><h3>Results</h3><div>Among 247 899 patients with glaucoma (mean [standard deviation] age: 60.1 [15.1] years, 56.2% female, 19.5% Black), 106 927 (43%) had ≥ 1 comorbid condition that could affect eye drop self-administration. Among 321 941 patients with DED (mean [standard deviation] age: 55.9 [16.1] years, 66.4% female, 12.6% Black), 156 811 (49%) had ≥ 1 such condition. Patients with ≥ 1 impairment affecting eye drop self-administration had 17% greater odds of glaucoma (aOR: 1.17, CI: 1.16–1.18) and 66% greater odds of DED (aOR: 1.66, CI: 1.65–1.68), compared with other patients. Persons with 2, 3, and ≥ 4 conditions that may affect eye drop administration had 27%, 39%, and 53% higher odds of glaucoma, respectively, compared with persons without such conditions (<em>P</em> &lt; 0.0001). Persons with 2, 3, and ≥ 4 health conditions that may impair eye drop administration had 76%, 121%, and 156% higher odds of DED, respectively (<em>P</em> &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>Nearly half of all patients with glaucoma or DED have ≥ 1 medical condition that may impair eye drop self-administration. Clinicians should assess patients' physical and mental capacity to self-administer topical ocular therapy. Some patients may benefit from alternative therapies that reduce or eliminate the need for eye drops.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages 431-439"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Resolution Anterior Segment-OCT-Guided Management of Iris Bombe Due to Pupillary Block 高分辨率前段oct引导下瞳孔阻塞导致虹膜爆炸的治疗。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-06-23 DOI: 10.1016/j.ogla.2025.06.001
Alessandro Siligato MD, Angelica Dipinto MD, Sara Bochicchio MD
{"title":"High-Resolution Anterior Segment-OCT-Guided Management of Iris Bombe Due to Pupillary Block","authors":"Alessandro Siligato MD,&nbsp;Angelica Dipinto MD,&nbsp;Sara Bochicchio MD","doi":"10.1016/j.ogla.2025.06.001","DOIUrl":"10.1016/j.ogla.2025.06.001","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Page e16"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease Progression, not Intraocular Pressure, Should Guide Escalation of Treatment in Glaucoma 青光眼的治疗应以疾病进展而非眼压为指导。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-04-19 DOI: 10.1016/j.ogla.2025.04.005
Giovanni Montesano MD, PhD, David F. Garway-Heath MD, FRCOphth, Gus Gazzard MA(Cantab), FRCOphth
{"title":"Disease Progression, not Intraocular Pressure, Should Guide Escalation of Treatment in Glaucoma","authors":"Giovanni Montesano MD, PhD,&nbsp;David F. Garway-Heath MD, FRCOphth,&nbsp;Gus Gazzard MA(Cantab), FRCOphth","doi":"10.1016/j.ogla.2025.04.005","DOIUrl":"10.1016/j.ogla.2025.04.005","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages 427-430"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lens Capsule Deposit in an Eye with Prior Trabeculectomy 先前小梁切除术的眼内晶状体囊沉积。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-06-29 DOI: 10.1016/j.ogla.2025.06.002
Helena Gali MD , Wendy W. Liu MD, PhD
{"title":"Lens Capsule Deposit in an Eye with Prior Trabeculectomy","authors":"Helena Gali MD ,&nbsp;Wendy W. Liu MD, PhD","doi":"10.1016/j.ogla.2025.06.002","DOIUrl":"10.1016/j.ogla.2025.06.002","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Page e17"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Glaucoma Society 40th Anniversary 美国青光眼协会成立40周年:我们的进步和未来的镜头。
IF 3.2 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.ogla.2025.07.002
Carla J. Siegfried MD , Gregory L. Skuta MD
{"title":"American Glaucoma Society 40th Anniversary","authors":"Carla J. Siegfried MD ,&nbsp;Gregory L. Skuta MD","doi":"10.1016/j.ogla.2025.07.002","DOIUrl":"10.1016/j.ogla.2025.07.002","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"8 5","pages":"Pages S2-S5"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ophthalmology. Glaucoma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1